Overview

Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer

Status:
Terminated
Trial end date:
2017-07-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Succinate of Solifenacin reduces the OverActive Bladder syndrome occurring during prostate irradiation.
Phase:
Phase 3
Details
Lead Sponsor:
Center Eugene Marquis
Treatments:
Solifenacin Succinate